ATEMPT

NCT01853748 📎

Regimen

Experimental
T-DM1 3.6 mg/kg IV every 3 weeks x 17 cycles (1 year).
Control
Paclitaxel weekly x 12 plus trastuzumab weekly x 12 then trastuzumab to complete 1 year (TH, the APT regimen).

Population

HER2-positive stage I (pT1 N0) early breast cancer considered low risk for recurrence, eligible for adjuvant-only therapy.

Key finding

ATEMPT showed adjuvant T-DM1 yields excellent 3-year iDFS in stage I HER2+ breast cancer and offers a chemotherapy-free alternative to TH. Not designed for formal non-inferiority but supports T-DM1 as an option in selected low-risk patients.

Source: PMID 38935923

Timeline

  • Publication: 2024 Nov

Guideline citations

  • NCCN BREAST